- Home
- TBRG vs CERS Comparison
TBRG vs CERS Comparison
Compare TBRG & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBRG
- CERS
- Stock Information
- Founded
- TBRG 1979
- CERS 1991
- Country
- TBRG United States
- CERS United States
- Employees
- TBRG N/A
- CERS N/A
- Industry
- TBRG
- CERS EDP Services
- Sector
- TBRG
- CERS Technology
- Exchange
- TBRG NYSE
- CERS Nasdaq
- Market Cap
- TBRG 393.0M
- CERS 347.3M
- IPO Year
- TBRG N/A
- CERS 1997
- Fundamental
- Price
- TBRG $23.93
- CERS $1.27
- Analyst Decision
- TBRG Buy
- CERS Strong Buy
- Analyst Count
- TBRG 3
- CERS 2
- Target Price
- TBRG $23.67
- CERS $3.50
- AVG Volume (30 Days)
- TBRG 162.7K
- CERS 1.1M
- Earning Date
- TBRG 05-07-2025
- CERS 05-01-2025
- Dividend Yield
- TBRG N/A
- CERS N/A
- EPS Growth
- TBRG N/A
- CERS N/A
- EPS
- TBRG N/A
- CERS N/A
- Revenue
- TBRG $345,737,000.00
- CERS $185,144,000.00
- Revenue This Year
- TBRG $5.23
- CERS $22.37
- Revenue Next Year
- TBRG $5.45
- CERS $8.46
- P/E Ratio
- TBRG N/A
- CERS N/A
- Revenue Growth
- TBRG 3.56
- CERS 13.06
- 52 Week Low
- TBRG $8.99
- CERS $1.12
- 52 Week High
- TBRG $32.00
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- TBRG 40.93
- CERS 46.48
- Support Level
- TBRG $23.40
- CERS $1.21
- Resistance Level
- TBRG $24.58
- CERS $1.35
- Average True Range (ATR)
- TBRG 0.98
- CERS 0.06
- MACD
- TBRG -0.08
- CERS -0.00
- Stochastic Oscillator
- TBRG 25.27
- CERS 38.89
About TBRG TRUBRIDGE INC
TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are Revenue Cycle Management (RCM), (ii) Electronic Health Records (EHR), and (iii) Patient Engagement The company derives maximum revenue from the RCM segment.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.